Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib 300 mg versus 150 mg in current smokers with advanced NSCLC after platinum failure
NL-OMON36738Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoint: Progression-free survival. Started Oct 2010; status: active, not recruiting.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON36738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36738.